List view / Grid view
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
A US study has overcome a major obstacle in cell-free DNA (cfDNA) testing or liquid biopsy, offering promising advancements in disease diagnosis and monitoring.
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
Japanese researchers have designed a pure capped mRNA vaccine which has shown a better protein production in the immune system.
Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.
Cell line development (CLD) is a critical, early step when entering the development phase of a biotherapeutic. Access to specialist skills and experience, either in-house or remotely, and to multiple technologies and equipment can prove invaluable for the timely and successful completion of this stage. Here, Dr Alison Porter addresses…
Drug Target Review’s Taylor Mixides interviews Cellarity's CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies.
South Korean researchers have developed a hydrogel using a uterus-derived decellularised extracellular matrix, bringing hope for those challenged with infertility.
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
Tomographic phase microscopy in flow cytometry showcases its ability to accurately measure intracellular lipid droplets.
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
Spanish researchers looking at two crucial proteins uncover how cells release mucin and insulin, leading to new methods to reset deregulation.
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
